<DOC>
	<DOC>NCT00247481</DOC>
	<brief_summary>This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast cancer.</brief_summary>
	<brief_title>ZD1839 (Iressaâ„¢) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically or cytologically confirmed breast cancer at a metastatic stage. Uni or bidimensionally measurable lesions (10 mm or 20 mm) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria World Health Organisation (WHO) performance status (PS) of 0 to 2 Life expectancy of greater than 12 weeks Normal cardiac function (left ventricular ejection fraction [LVEF] by isotopic examination greater than or equal to 55%) Symptomatic leptomeningeal metastasis Concomitant infectious disease Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy Incomplete healing from previous oncologic or other surgery Absolute neutrophil count (ANC) less than 1.5 x 109/litre (L) or platelets less than 100 x 109/L Serum creatinine greater than 1.5 times the ULRR or clearance &lt; 60 ml/min ALT or AST greater than 2.5 times the ULRR ALP &gt; 5 times the ULRR ALP &gt; 2.5 times the ULRR and ALT or AST greater than 1.5 times the ULRR</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>